Symjepi Now Available in Pharmacies
July 9, 2019 – Adamis Pharmaceuticals and Sandoz have announced the immediate launch of Symjepi™ (epinephrine) injection 0.3mg and 0.15mg in pharmacies across the United States. The product, which was previously available only through hospitals and clinics, is indicated to provide emergency treatment for Type 1 allergic reactions, including anaphylaxis.
The launch comes at a time when Mylan’s EpiPen® (epinephrine) 3mg and EpiPen Jr® (epinephrine) 0.15mg remain in shortage, and Amneal Pharmaceuticals expects supply issues to impact its own epinephrine injection, Adrenaclick® (epinephrine). EpiPen and EpiPen Jr have been in shortage for more than a year due to manufacturing issues at the single U.S.-based plant where they are produced. Demand for these and similar products typically increases each year during the third quarter, as parents and schools prepare for the coming school year.
Symjepi is one of several epinephrine injection products currently available on the market in addition to EpiPen, EpiPen Jr, and Adrenaclick. Others include Kaléo Pharma’s Auvi-Q® (epinephrine) and generic versions of epinephrine injection from Mylan and Teva.
Available at a list price of $250 for a two-pack of prefilled syringes, Symjepi’s recommended dosing is one 0.3mg prefilled syringe for patients who weigh at least 30kg (66 pounds), or one 0.15mg prefilled syringe for patients who weigh 15-30kg (33-66 pounds). A second syringe can be administered if needed, but no more than two syringes should be used to treat a reaction. The individual should also receive immediate care from medical personnel, as severe allergic reactions can be life-threatening.